메뉴 건너뛰기




Volumn 69, Issue 5, 2015, Pages 282-286

New drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB);Kurze Übersicht über neue Medikamente zur Therapie der multiresistenten Tuberkulose

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PRETOMANID; SUTEZOLID; TUBERCULOSTATIC AGENT;

EID: 84929326626     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0034-1391920     Document Type: Article
Times cited : (3)

References (19)
  • 1
    • 84929355556 scopus 로고    scopus 로고
    • Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V 37. Informationsbericht. 2014; 108 125
    • (2014) 37. Informationsbericht , pp. 108-125
  • 2
    • 84861124193 scopus 로고    scopus 로고
    • Phase II dose-ranging trial of the early bactericidal activity of PA-824
    • Diacon A. H., Dawson R., du Bois J. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother: 2012; 56 3027 3031
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3027-3031
    • Diacon, A.H.1    Dawson, R.2    Du, B.J.3
  • 3
    • 84866177379 scopus 로고    scopus 로고
    • 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial
    • Diacon A. H., Dawson R., von Groote-Bidlingmaier F. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet: 2012; 380 986 993
    • (2012) Lancet , vol.380 , pp. 986-993
    • Diacon, A.H.1    Dawson, R.2    Von Groote-Bidlingmaier, F.3
  • 4
    • 84929745288 scopus 로고    scopus 로고
    • Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
    • Heinrich N., Dawson R., du Bois J. et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother: 2015; 10.1093/jac/dku553
    • (2015) J Antimicrob Chemother
    • Heinrich, N.1    Dawson, R.2    Du Bois, J.3
  • 5
    • 84899637134 scopus 로고    scopus 로고
    • Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis
    • Wallis R. S., Dawson R., Friedrich S. O. et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PloS one: 2014; 9 e94462
    • (2014) PloS One , vol.9 , pp. e94462
    • Wallis, R.S.1    Dawson, R.2    Friedrich, S.O.3
  • 6
    • 19944429772 scopus 로고    scopus 로고
    • A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    • Andries K., Verhasselt P., Guillemont J. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science: 2005; 307 223 227
    • (2005) Science , vol.307 , pp. 223-227
    • Andries, K.1    Verhasselt, P.2    Guillemont, J.3
  • 7
    • 35848948213 scopus 로고    scopus 로고
    • In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor
    • Huitric E., Verhasselt P., Andries K. et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother: 2007; 51 4202 4204
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 4202-4204
    • Huitric, E.1    Verhasselt, P.2    Andries, K.3
  • 8
    • 48749120676 scopus 로고    scopus 로고
    • Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
    • Rustomjee R., Diacon A. H., Allen J. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother: 2008; 52 2831 2835
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 2831-2835
    • Rustomjee, R.1    Diacon, A.H.2    Allen, J.3
  • 9
    • 66649090346 scopus 로고    scopus 로고
    • The diarylquinoline TMC207 for multidrug-resistant tuberculosis
    • Diacon A. H., Pym A., Grobusch M. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med: 2009; 360 2397 2405
    • (2009) N Engl J Med , vol.360 , pp. 2397-2405
    • Diacon, A.H.1    Pym, A.2    Grobusch, M.3
  • 10
    • 84861140844 scopus 로고    scopus 로고
    • Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance
    • Diacon A. H., Donald P. R., Pym A. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother: 2012; 56 3271 3276
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3271-3276
    • Diacon, A.H.1    Donald, P.R.2    Pym, A.3
  • 11
    • 84907377122 scopus 로고    scopus 로고
    • Multidrug-resistant tuberculosis and culture conversion with bedaquiline
    • Diacon A. H., Pym A., Grobusch M. P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med: 2014; 371 723 732
    • (2014) N Engl J Med , vol.371 , pp. 723-732
    • Diacon, A.H.1    Pym, A.2    Grobusch, M.P.3
  • 13
    • 33845947982 scopus 로고    scopus 로고
    • Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo 1 2 oxazoles
    • Sasaki H., Haraguchi Y., Itotani M. et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo 1 2 oxazoles. Journal of medicinal chemistry: 2006; 49 7854 7860
    • (2006) Journal of Medicinal Chemistry , vol.49 , pp. 7854-7860
    • Sasaki, H.1    Haraguchi, Y.2    Itotani, M.3
  • 14
    • 33845323336 scopus 로고    scopus 로고
    • OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
    • Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS medicine: 2006; 3 e466
    • (2006) PLoS Medicine , vol.3 , pp. e466
    • Matsumoto, M.1    Hashizume, H.2    Tomishige, T.3
  • 16
    • 79958718650 scopus 로고    scopus 로고
    • Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients
    • Diacon A. H., Dawson R., Hanekom M. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis: 2011; 15 949 954
    • (2011) Int J Tuberc Lung Dis , vol.15 , pp. 949-954
    • Diacon, A.H.1    Dawson, R.2    Hanekom, M.3
  • 17
    • 84861864703 scopus 로고    scopus 로고
    • Delamanid for multidrug-resistant pulmonary tuberculosis
    • Gler M. T., Skripconoka V., Sanchez-Garavito E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med: 2012; 366 2151 2160
    • (2012) N Engl J Med , vol.366 , pp. 2151-2160
    • Gler, M.T.1    Skripconoka, V.2    Sanchez-Garavito, E.3
  • 18
    • 84878776777 scopus 로고    scopus 로고
    • Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
    • Skripconoka V., Danilovits M., Pehme L. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J: 2013; 41 1393 1400
    • (2013) Eur Respir J , vol.41 , pp. 1393-1400
    • Skripconoka, V.1    Danilovits, M.2    Pehme, L.3
  • 19
    • 84926506498 scopus 로고    scopus 로고
    • Novel drugs against tuberculosis: A clinician's perspective
    • Olaru I. D., von Groote-Bidlingmaier F., Heyckendorf J. et al. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J: 2015; 45 1119 1131
    • (2015) Eur Respir J , vol.45 , pp. 1119-1131
    • Olaru, I.D.1    Von Groote-Bidlingmaier, F.2    Heyckendorf, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.